PD 325901

Drug Profile

PD 325901

Alternative Names: PD-0325901; PD-325901

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer BIOENSIS; Pfizer; SpringWorks Therapeutics; University of Alabama at Birmingham; University of Oxford
  • Class Aniline compounds; Antineoplastics; Benzamides; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors; Mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neurofibromatoses
  • Phase I Colorectal cancer
  • Preclinical Cervical cancer
  • Discontinued Breast cancer; Cancer; Malignant melanoma; Non-small cell lung cancer

Most Recent Events

  • 25 Sep 2017 SpringWorks Therapeutics, a Pfizer spinoff, is developing PD 325901
  • 25 Sep 2017 SpringWorks plans a phase III trial program for Neurofibromatosis
  • 01 Apr 2017 Preclinical trials in Cervical cancer (Combination therapy) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top